![Podobny obraz](http://mma.prnewswire.com/media/457404/Bioprojet_Logo.jpg?p=facebook)
In 1992, BIOPROJET shareholders created BIOPROJET PHARMA, a pharmaceutical company. Both companies have the same management. The activity of BIOPROJET PHARMA is centered on marketing in France of pharmaceutical compounds mostly issued from BIOPROJET’s research and development. Since 2002 BIOPROJET PHARMA has gradually extended the geographic coverage of Tiorfan®/Hidrasec® (Racecadotril) to major European markets and overseas markets. It is marketed today in more than 30 countries, mostly through licensees. This geographic base will continue to expand with new approvals and launches across all the continents.